Welcome to BOPA
Latest news from BOPA
For details on the forthcoming
BOPA Study Days
BOPA are hosting 4 study days with Dr Elaine Vickers on the following topics:
The Science of Targeted Cancer Treatments: 19th & 22nd May 2015
Targeted Treatments for Haematological: 8th & 9th September 2015
Click here for more information
First Early Access to Medicines (EAMS) Scientific Opinion issued by MHRA
The MHRA has issued its first Early Access to Medicines (EAMS) scientific opinion.
It is for a product called pembrolizumab, used to treat advanced melanoma which has spread or cannot be removed by surgery and has progressed after other treatments. The MHRA assessment team considered that pembrolizumab had been shown to slow the progression of cancer in a condition where other treatments currently have poor results.
Details of the scientific opinion (https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-pembrolizumab-mk-3475) can be found on the MHRA website, as well as background information on EAMS (https://www.gov.uk/apply-for-the-early-access-to-medicines-scheme-eams).